Llwytho...

Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma

The management of advanced renal cell carcinoma (RCC) has dramatically changed over the past decade. Therapies that target the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways have considerably expanded treatment options; however, most patients with advance...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Nat Rev Urol
Prif Awduron: Carlo, Maria I., Voss, Martin H., Motzer, Robert J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2016
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5532875/
https://ncbi.nlm.nih.gov/pubmed/27324121
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrurol.2016.103
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!